| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ASTHMA |
1 Department of Pulmonary Rehabilitation, Beatrixoord, Haren, University Medical Center and University of Groningen, the Netherlands
2 Department of Pulmonology, University Medical Center and University of Groningen, the Netherlands
3 Department of Epidemiology and Statistics, University Medical Center and University of Groningen, the Netherlands
4 Beatrix Children’s Hospital, University Medical Center and University of Groningen, the Netherlands
5 Department of Pathology and Laboratory Medicine, University Medical Center and University of Groningen, the Netherlands
Correspondence to:
Correspondence to:
Dr D S Postma
Department of Pulmonology, University Medical Center Groningen, Hanzeplein 1, P O Box 30.001, 9700 RB Groningen, The Netherlands; d.s.postma{at}int.umcg.nl
Background: Inhaled corticosteroids (ICS) provide short term benefits in asthma but the long term effects are still unknown.
Methods: 281 patients diagnosed with moderate to severe asthma in 1963–75 were re-examined in 1991–9. Information was collected on forced expiratory volume in 1 second (FEV1), bronchial hyperresponsiveness, atopy, smoking, use and dosage of oral and ICS. Patients were included in the analyses if they had at least three FEV1 measurements during two consecutive years after the age of 30 and used ICS during follow up.
Results: Analyses were performed on 122 patients. During a median follow up period of 23 years, 71 men and 51 women had on average 37 and 40 individual FEV1 measurements, respectively. Linear mixed effect models showed that men had a mean annual decline in FEV1 of 20.6 ml/year less after ICS initiation than before (p = 0.011), and in women the decline in FEV1 was 3.2 ml/year less (p = 0.73). In individuals with <5 pack years of smoking the decline in FEV1 was 36.8 ml/year less after ICS institution in men (p = 0.0097) and 0.8 ml/year less in women (p = 0.94), the difference between the sexes being significant (p = 0.045). These effects were not observed in those with 
5 pack years smoking. A higher daily dose of ICS was associated with a smaller decline in FEV1 in men (p = 0.006), an effect not observed in women.
Conclusion: Treatment with ICS in adult patients with moderate to severe asthma was associated with a reduction in the decline in FEV1 over a 23 year follow up period in men who had smoked <5 pack years. This effect was dose dependent and was not present in women or in men with 5 pack years of smoking at follow up. The lack of effect of ICS on the decline in FEV1 in women needs further study.
Keywords: asthma; lung function decline; inhaled corticosteroids; smoking; sex
Relevant Article
Thorax 2006 61: 93.
This article has been cited by other articles:
|
|
 |
|
  G. Braganza, R. Chaudhuri, and N. C. Thomson Review: Treating patients with respiratory disease who smoke Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 95 - 107. [Abstract] [PDF]
|
|
|
|
 |
|
 M. R. Sears Lung function decline in asthma Eur. Respir. J., September 1, 2007; 30(3): 411 - 413. [Full Text] [PDF]
|
|
|
|
|
|
T. R. Bai, J. M. Vonk, D. S. Postma, and H. M. Boezen Severe exacerbations predict excess lung function decline in asthma Eur. Respir. J., September 1, 2007; 30(3): 452 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. Thomson Smokers with Asthma: What Are the Management Options? Am. J. Respir. Crit. Care Med., April 15, 2007; 175(8): 749 - 750. [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Soriano, D. D. Sin, X. Zhang, P. G. Camp, J. A. Anderson, N. R. Anthonisen, A. S. Buist, P. S. Burge, P. M. Calverley, J. E. Connett, et al. A Pooled Analysis of FEV1 Decline in COPD Patients Randomized to Inhaled Corticosteroids or Placebo Chest, March 1, 2007; 131(3): 682 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P J F M Merkus and J C de Jongste Inhaled corticosteroids and long term outcome in adults with asthma. Thorax, November 1, 2006; 61(11): 1011 - 1011. [Full Text] [PDF]
|
|
|
|
|
|
C. Jenkins Mars and Venus in the GP's office. Eur. Respir. J., August 1, 2006; 28(2): 259 - 261. [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Holgate, Y. Yang, H.-M. Haitchi, R. M. Powell, J. W. Holloway, H. Yoshisue, Y. Y. Pang, J. Cakebread, and D. E. Davies The Genetics of Asthma: ADAM33 as an Example of a Susceptibility Gene. Proceedings of the ATS, July 1, 2006; 3(5): 440 - 443. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
